BMY 7378 dihydrochloride (BMY7378 HCl) , α1D-adrenergic receptor antagonist, is a weak partial agonist/antagonist of 5-HT1A receptor.

D2 receptor:7.4(pIC50), 5-HT1C:6.4(pIC50), α1D-adrenoceptor:8.2(pKi), 5-HT1A:8.3(pIC50), α2C-adrenoceptor:6.54(pKi)

The antagonistic effect produced by WAY 100635 was mediated by increasing the concentration of 5-HT to 300 μM with an IC50 of 0.95 nM. PluriSIn 1 causes central cell death by activating apoptosis.PluriSIn 1 produces ER stress by interacting with hPSCs.PluriSIns 1 (20 μM) has an inhibitory effect on teratoma formation by undifferentiated hPSCs, and it also inhibits the development of mPSCs and mouse embryos.PluriSIns 1 (20 μM) induces a protein-like response to hPSCs by interacting with hPSCs. PluriSIns 1 (20 μM) induced an approximately 30% reduction in protein synthesis by interacting with hPSCs.

The antagonistic effect produced by WAY 100635 was mediated by increasing the concentration of 5-HT to 300 μM with an IC50 of 0.95 nM. PluriSIn 1 causes central cell death by activating apoptosis.PluriSIn 1 produces ER stress by interacting with hPSCs.PluriSIns 1 (20 μM) has an inhibitory effect on teratoma formation by undifferentiated hPSCs, and it also inhibits the development of mPSCs and mouse embryos.PluriSIns 1 (20 μM) induces a protein-like response to hPSCs by interacting with hPSCs. PluriSIns 1 (20 μM) induced an approximately 30% reduction in protein synthesis by interacting with hPSCs.

Phosphatase activities are determined on immunoprecipitates of the phosphatases. Briefly, 2×106 K562 cells are treated for 18 hr with Salubrinal (20 μM), PSI (10 nM), the combination of both drugs or okadaic acid (100 nM). After washing with PBS, cells are lysed for 15 min on ice either in PP1LB (for determination of PP1γ-activity; 20 mM Tris-HCl, pH 7.5, 1% Triton X-100, 10% glycerol, 132 mM NaCl, Roche complete protease inhibitor ) or in RIPA (for PP2A), supplemented with Roche complete protease inhibitor). Cell lysates containing 500 μg (PP1γ) or 300 μg (PP2A) protein are immunoprecipitated overnight at 4°C with 2-3 μg of the appropriate antibodies and then incubated with Protein A-Sepharose. Immunoprecipitates are washed three times in lysis buffer, followed by resuspension in phosphatase assay buffer (PP2A: 20 mM Tris-HCl, pH7.5, 0.1 mM CaCl2; PP1γ: 50 mM Tris HCl pH 7.0, 0.2 mM MnCl2, 0.1 mM CaCl2, 125 μg/mL BSA, 0.05% Tween 20), supplemented with 100 μM 6,8-difluoro-4-methyl-umbelliferyl phosphate (DiFMUP). Precipitates are allowed to react with substrate for 1 hr at 37°C on an Eppendorf Thermoshaker, centrifuged and DiFMU fluorescence is measured on a BioTek Lambda Fluoro 320 microplate reader (360 nmex/460 nmem). Phosphatase activities are given as percent change relative to the control (DMSO treated cells)[1].